Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

Rheumatology Department, Hôpital Robert Ballanger, Aulnay sous Bois, France.
Arthritis research & therapy (Impact Factor: 4.12). 02/2005; 7(3):R545-51. DOI: 10.1186/ar1715
Source: PubMed

ABSTRACT The development of drug-induced lupus remains a matter of concern in patients treated with anti-tumour necrosis factor (TNF) alpha. The incidence of such adverse effects is unknown. We undertook a retrospective national study to analyse such patients. Between June and October 2003, 866 rheumatology and internal medicine practitioners from all French hospital centres prescribing anti-TNF in rheumatic diseases registered on the website of the 'Club Rhumatismes et Inflammation' were contacted by email to obtain the files of patients with TNF-induced systemic lupus erythematosus. Twenty-two cases were collected, revealing two aspects of these manifestations. Ten patients (six patients receiving infliximab, four patients receiving etanercept) only had anti-DNA antibodies and skin manifestations one could classify as 'limited skin lupus' or 'toxidermia' in a context of autoimmunity, whereas 12 patients (nine patients receiving infliximab, three patients receiving etanercept) had more complete drug-induced lupus with systemic manifestations and at least four American Congress of Rheumatology criteria. One patient had central nervous system manifestations. No patients had lupus nephritis. The signs of lupus occurred within a mean of 9 months (range 3-16 months) in patients treated with infliximab and within a mean of 4 months (range 2-5 months) in patients treated with etanercept. In all cases after diagnosis was determined, anti-TNF was stopped and specific treatment introduced in eight patients: two patients received intravenous methylprednisolone, four patients received oral steroids (15-35 mg/day), and two patients received topical steroids. Lupus manifestations abated within a few weeks (median 8 weeks, standard deviation 3-16) in all patients except one with longer-lasting evolution (6 months). At that time, cautious estimations (unpublished data from Schering Plough Inc. and Wyeth Inc.) indicated that about 7700 patients had been exposed to infliximab and 3000 to etanercept for inflammatory arthritides in France. It thus appears that no drug was more implicated than the other in lupus syndromes, whose incidence was 15/7700 = 0.19% with infliximab and 7/3800 = 0.18% with etanercept. Clinicians should be aware that lupus syndromes with systemic manifestations may occur in patients under anti-TNF alpha treatment.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rheumatoid arthritis (RA) is a complex inflammatory disorder associated with synovitis and joint destruction that affects an estimated 1·3 million Americans and causes significant morbidity, a reduced life-span and lost work productivity. The use of biological therapies for the treatment of RA is costly, and the selection of therapies is still largely empirical and not guided by the underlying biological features of the disease in individual patients. The synovitis associated with RA is characterized by an influx of B and T cells, macrophages and neutrophils and the expansion of fibroblast-like synoviocytes, which form pannus and lead to cartilage and bone destruction. RA is associated with synovial production of rheumatoid factor (RF) and anti-citrullinated protein autoantibodies (ACPA) and with the production of inflammatory cytokines, including interleukin (IL)-1, IL-6, IL-17 and tumour necrosis factor (TNF)-α, which are targets for RA therapeutics. Recent ideas about the pathogenesis of RA emphasize a genetic predisposition to develop RA, a preclinical phase of disease that is associated with the production of ACPA and the development of symptomatic disease following inflammatory initiating events that are associated with expression of citrullinated epitopes in the joints of patients. However, we still have a limited understanding of the cytokine and intracellular pathways that regulate ACPA levels. In humans, therapy with biological agents affords a unique opportunity to better understand the cytokine and signalling pathways regulating ACPA levels and the impact of ACPA level changes on disease activity. In this study we summarize the effect of RA therapies on ACPA levels and B cell responses.
    Clinical & Experimental Immunology 07/2013; 173(1). · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. TNFα antagonists are effective for treating rheumatoid arthritis and other inflammatory diseases, but their use can be complicated by lupus-like phenomena. We investigated the role of TNFα in murine lupus.Methods. TLR7 ligand-driven lupus was induced in B6 and B6- TNFα-/- mice using pristane. Autoantibodies and type I interferon (IFN-I) production were measured and the effects on IFN-I-producing plasmacytoid dendritic cells (pDCs), Ly6Chi monocytes, and TNFα-producing neutrophils were determined.Results. TNFα-/- mice did not spontaneously develop autoantibodies or clinical manifestations, suggesting that TNFα deficiency alone is insufficient to cause lupus. Although IFN-I levels were comparable in untreated TNFα-/- and B6 mice, untreated TNFα-/- mice had increased circulating pDCs and “pDC-like” cells, enhancing their potential to make IFN-I. When treated with pristane, TNFα-/- mice developed more severe lupus than controls with increased levels of anti-Sm/RNP autoantibodies, IFN-I, pDCs, and peritoneal inflammatory (Ly6Chi) monocytes. Neutrophils, which promoted resolution of inflammation, were decreased considerably in pristane-treated TNFα-/- mice, whereas the inflammatory monocyte and pDC responses and IFN-I were increased and prolonged.Conclusions. Low levels of TNFα increased circulating pDC numbers, enhancing the potential to make IFN-I. But this did not lead to IFN-I production or autoimmunity unless there was concomitant exposure to endogenous TLR7 ligands released from dead cells following pristane treatment. In patients, the rate of clearance of dead cells along with TNFα levels may influence who will develop lupus when treated with TNFα inhibitors. © 2014 American College of Rheumatology.
    Arthritis & Rheumatology. 09/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biologic agents have substantially advanced the treatment of immunological disorders, including chronic inflammatory and autoimmune diseases. However, these drugs are often associated with adverse events (AEs), including allergic, immunological and other unwanted reactions. AEs can affect almost any organ or system in the body and can occur immediately, within minutes to hours, or with a delay of several days or more after initiation of biologic therapy. Although some AEs are a direct consequence of the functional inhibition of biologic-agent-targeted antigens, the pathogenesis of other AEs results from a drug-induced imbalance of the immune system, intermediary factors and cofactors, a complexity that complicates their prediction. Herein, we review the AEs associated with biologic therapy most relevant to rheumatic and immunological diseases, and discuss their underlying pathogenesis. We also include our recommendations for the medical management of such AEs. Increased understanding and improved risk management of AEs induced by biologic agents will enable better use of these versatile immune-response modifiers.
    Nature Reviews Rheumatology 08/2014; · 9.75 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014